The efficacy of nilotinib treatment approaches in frontline CML

0 Views
administrator
administrator
07/08/23

Timothy Hughes, MD, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, shares some insights into a study comparing the use of nilotinib versus a nilotinib plus imatinib switch approach for the frontline treatment of chronic myeloid leukemia (CML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next